|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2004-4-9
|
|
pubmed:abstractText |
Temozolomide (TMZ) and 1, 3-bis (2-chloroethyl)-1-nitrosourea (BCNU) are reported to be active agents in anaplastic glioma (AG). TMZ has also been shown to deplete alkyltransferase, a DNA repair enzyme that contributes to nitrosourea resistance. The objective of the current study was to determine the efficacy and toxicity profile of a combination of these agents before radiotherapy in newly diagnosed AG.
|
|
pubmed:grant |
http://linkedlifedata.com/resource/pubmed/grant/CA62399,
http://linkedlifedata.com/resource/pubmed/grant/CA62405,
http://linkedlifedata.com/resource/pubmed/grant/CA62407,
http://linkedlifedata.com/resource/pubmed/grant/CA62412,
http://linkedlifedata.com/resource/pubmed/grant/CA62421,
http://linkedlifedata.com/resource/pubmed/grant/CA62422,
http://linkedlifedata.com/resource/pubmed/grant/CA62426,
http://linkedlifedata.com/resource/pubmed/grant/CA62455,
http://linkedlifedata.com/resource/pubmed/grant/M01-RR00042,
http://linkedlifedata.com/resource/pubmed/grant/M01-RR00056,
http://linkedlifedata.com/resource/pubmed/grant/M01-RR00079,
http://linkedlifedata.com/resource/pubmed/grant/M01-RR00633,
http://linkedlifedata.com/resource/pubmed/grant/M01-RR03186
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
pubmed-author:ChangSusan MSM,
pubmed-author:FineHowardH,
pubmed-author:FinkKaren LKL,
pubmed-author:GreenbergHarryH,
pubmed-author:HessKennethK,
pubmed-author:JaeckleKurt AKA,
pubmed-author:JunckLarryL,
pubmed-author:KuhnJohnJ,
pubmed-author:MehtaMineshM,
pubmed-author:PradosMichael DMD,
pubmed-author:RobinsH IanHI,
pubmed-author:ScholdCliffordC,
pubmed-author:YungW K AlfredWK
|
|
pubmed:copyrightInfo |
Copyright 2004 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
100
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1712-6
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:15073861-Adolescent,
pubmed-meshheading:15073861-Adult,
pubmed-meshheading:15073861-Aged,
pubmed-meshheading:15073861-Antineoplastic Agents, Alkylating,
pubmed-meshheading:15073861-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15073861-Brain Neoplasms,
pubmed-meshheading:15073861-Carmustine,
pubmed-meshheading:15073861-Dacarbazine,
pubmed-meshheading:15073861-Disease Progression,
pubmed-meshheading:15073861-Drug Resistance, Neoplasm,
pubmed-meshheading:15073861-Female,
pubmed-meshheading:15073861-Glioma,
pubmed-meshheading:15073861-Humans,
pubmed-meshheading:15073861-Male,
pubmed-meshheading:15073861-Middle Aged,
pubmed-meshheading:15073861-Neoadjuvant Therapy,
pubmed-meshheading:15073861-Radiotherapy, Adjuvant,
pubmed-meshheading:15073861-Survival Analysis
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
|
|
pubmed:affiliation |
Department of Neurological Surgery, Neuro-Oncology Service, University of California at San Francisco, San Francisco, California 94143, USA. changs@neurosurg.ucsf.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study,
Clinical Trial, Phase II
|
